drugset / Trial / NCT02407821
The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)
Phase 2
Terminated
25 enrolled
University Health Network, Toronto
McMaster University · collabUnity Health Toronto · collabUniversity of Toronto · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this study the investigators hypothesize that antidepressant therapy may improve the overall welling of patients with acute or chronic kidney disease when given around the time of starting chronic dialysis therapy. This study is a pilot, randomized controlled trial that aims to examine whether prescribing oral escitalopram to all incident dialysis patients is safe and feasible.
Timeline
- Start
- 2015-03
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Escitalopram | Small molecule | 10 mg | Oral |